Turkish Journal of Nephrology
Orginal Article

Hepatitis C Prevalence in Hemodialysis Patients and the Results of New Antiviral Therapy

1.

Department of Infectious Diseases, University of Health Sciences, Erzurum Regional Training and Research Hospital, Erzurum, Turkey

2.

Department of Chest Diseases, University of Health Sciences, Erzurum Regional Training and Research Hospital, Erzurum, Turkey

3.

Department of Nephrology, University of Health Sciences, Erzurum Regional Training and Research Hospital, Erzurum, Turkey

Turkish J Nephrol 2019; 28: 103-108
DOI: 10.5152/turkjnephrol.2019.3311
Read: 362 Downloads: 142 Published: 22 April 2019

Objective: Hepatitis C virus (HCV) is more common in patients undergoing dialysis compared to the normal population. The objective of this study was to investigate the incidence of hepatitis C in patients undergoing hemodialysis and to share the results of the antiviral drugs used in the treatment of our patients with HCV.

Materials and Methods: A total of 235 dialysis patients who had applied to the Outpatient Department of Infectious Diseases and Nephrology between January 2017 and December 2017 were retrospectively evaluated.

Results: The percentage of the anti-HCV positivity was 12.7%, and 73% of patients with anti-HCV positivity showed the HCV-RNA positivity. Genotyping revealed that 77.2% were 1b, 18.1% were 1a, and 4.5% were 3a. The treatment was planned according to the results of the genotype analysis. The HCV-RNA analysis was not performed in two anti-HCV positive patients because they refused to give blood, and 10 patients refused the treatment. For 12 non-cirrhotic genotype 1b patients who were not treated previously, a treatment protocol by adding dasabuvir to a combination of ombitasvir and paritaprevir/ritonavir was prepared. All patients who completed a 12-week treatment course became 100% HCV-RNA negative in the 1st, 3rd, and 6th month.

Conclusion: The treatment of patients undergoing hemodialysis infected with the HCV genotype 1b with an ombitasvir/paritaprevir/ritonavir/dasabuvir combination was very effective.

Cite this article as: Çelik N, Çelik O, Sevinç C, Ünal O. Hepatitis C Prevalence in Hemodialysis Patients and the Results of New Antiviral Therapy. Turk J Nephrol 2019; 28(2): 103-8.

Files
EISSN 2667-4440
3